Literature DB >> 12721664

B7-H1 pathway and its role in the evasion of tumor immunity.

Haidong Dong1, Lieping Chen.   

Abstract

B7-H1 is a recently identified member of the B7 family molecules. Upon ligation to its receptors on T cells it regulates activation and differentiation of T cells. B7-H1 preferentially costimulates IL-10 production in resting T cells and further induces the apoptosis of activated T cells. PD-1 is a receptor of B7-H1 and is shown to mediate the inhibition of activated T cell response, presumably by inhibiting cell cycle progression. The expression of B7-H1 protein is limited to macrophage lineage of cells in normal tissues, although its mRNA transcription is found in a broad range of tissues. In contrast, B7-H1 is abundant in various human cancers. The tumor-associated B7-H1 increases apoptosis of antigen specific T cells, leading to growth of immunogenic tumor growth in vivo. Current data suggest that B7-H1 regulates the organ-specific tolerance in normal tissue and may contribute to immune evasion by cancers. Selective manipulation of B7-H1 pathway thus aids in the design of new regimens in the treatment of human autoimmune disease and the control of malignant cancers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12721664     DOI: 10.1007/s00109-003-0430-2

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  47 in total

1.  PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine.

Authors:  T Okazaki; A Maeda; H Nishimura; T Kurosaki; T Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

Review 2.  A fresh look at tumor immunosurveillance and immunotherapy.

Authors:  M J Smyth; D I Godfrey; J A Trapani
Journal:  Nat Immunol       Date:  2001-04       Impact factor: 25.606

3.  Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues.

Authors:  Masayoshi Ishida; Yoshiko Iwai; Yoshimasa Tanaka; Taku Okazaki; Gordon J Freeman; Nagahiro Minato; Tasuku Honjo
Journal:  Immunol Lett       Date:  2002-10-21       Impact factor: 3.685

Review 4.  T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance.

Authors:  P A Cohen; L Peng; J Kjaergaard; G E Plautz; J H Finke; G K Koski; B J Czerniecki; S Shu
Journal:  Crit Rev Immunol       Date:  2001       Impact factor: 2.214

Review 5.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

Review 6.  Natural selection of tumor variants in the generation of "tumor escape" phenotypes.

Authors:  Hung T Khong; Nicholas P Restifo
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

7.  CD86 (B7-2) on human B cells. A functional role in proliferation and selective differentiation into IgE- and IgG4-producing cells.

Authors:  P Jeannin; Y Delneste; S Lecoanet-Henchoz; J F Gauchat; J Ellis; J Y Bonnefoy
Journal:  J Biol Chem       Date:  1997-06-20       Impact factor: 5.157

8.  Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.

Authors:  Y Agata; A Kawasaki; H Nishimura; Y Ishida; T Tsubata; H Yagita; T Honjo
Journal:  Int Immunol       Date:  1996-05       Impact factor: 4.823

9.  B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum.

Authors:  L Chen; P McGowan; S Ashe; J V Johnston; I Hellström; K E Hellström
Journal:  Cancer Res       Date:  1994-10-15       Impact factor: 12.701

10.  Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Authors:  Y Ishida; Y Agata; K Shibahara; T Honjo
Journal:  EMBO J       Date:  1992-11       Impact factor: 11.598

View more
  106 in total

Review 1.  Immunology of B7-H1 and its roles in human diseases.

Authors:  Hideto Tamura; Kiyoyuki Ogata; Haidong Dong; Lieping Chen
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

Review 2.  PD-1, gender, and autoimmunity.

Authors:  Ravi K Dinesh; Bevra H Hahn; Ram Pyare Singh
Journal:  Autoimmun Rev       Date:  2010-04-28       Impact factor: 9.754

3.  Inhibitors of B7-CD28 costimulation in urologic malignancies.

Authors:  R Houston Thompson; Eugene D Kwon; James P Allison
Journal:  Immunotherapy       Date:  2009-01       Impact factor: 4.196

4.  The increase of circulating PD-L1-expressing CD68(+) macrophage in ovarian cancer.

Authors:  Qiu-Xia Qu; Qin Huang; Yu Shen; Yi-Bei Zhu; Xue-Guang Zhang
Journal:  Tumour Biol       Date:  2015-11-06

Review 5.  Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment.

Authors:  Thomas F Gajewski; Mercedes Fuertes; Robbert Spaapen; Yan Zheng; Justin Kline
Journal:  Curr Opin Immunol       Date:  2010-12-23       Impact factor: 7.486

6.  The immunomodulatory proteins B7-DC, B7-H2, and B7-H3 are differentially expressed across gestation in the human placenta.

Authors:  Margaret G Petroff; Elza Kharatyan; Donald S Torry; Lesya Holets
Journal:  Am J Pathol       Date:  2005-08       Impact factor: 4.307

Review 7.  The many sounds of T lymphocyte silence.

Authors:  Ignacio Melero; Ainhoa Arina; Lieping Chen
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

8.  Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue.

Authors:  Elaine Bigelow; Katherine M Bever; Haiying Xu; Allison Yager; Annie Wu; Janis Taube; Lieping Chen; Elizabeth M Jaffee; Robert A Anders; Lei Zheng
Journal:  J Vis Exp       Date:  2013-01-03       Impact factor: 1.355

Review 9.  The biology of human lymphoid malignancies revealed by gene expression profiling.

Authors:  Louis M Staudt; Sandeep Dave
Journal:  Adv Immunol       Date:  2005       Impact factor: 3.543

10.  Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses.

Authors:  Leandro M Colli; Mitchell J Machiela; Timothy A Myers; Lea Jessop; Kai Yu; Stephen J Chanock
Journal:  Cancer Res       Date:  2016-05-18       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.